Pharmacokinetic ProfilesPhase 1NCT07068841
Pharmacokinetic Effect of Y-3 on Repaglinide，Warfarin and Omeprazole in Healthy Participants
A Phase 1 study testing sequentially single use of repaglinide, warfarin and omeprazole or combined with Y-3 in people with Pharmacokinetic Profiles and Y-3 for Injection, run by Neurodawn Pharmaceutical Co., Ltd. at 1 site in China.
Trial summary
The primary goal of this clinical trial is to evaluate the effect of Y-3 for injection on the pharmacokinetic profile of the sensitive finger substrates repaglinide tablets, warfarin sodium tablets, and omeprazole enteric-coated capsules for CYP2C8, CYP2C9, and CYP2C19 in Chinese healthy participants, to evaluate… Read more about this study
- Who is it for?
- Ages 18 to 50 yearsHealthy volunteers can take part
- Conditions the study is for
- Pharmacokinetic Profiles, Y-3 for Injection, Drug-drug Interaction
- What is being tested?
- sequentially single use of repaglinide, warfarin and omeprazole or combined with Y-3
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 24 participants
- Where
- 1 siteChina
- Study dates
- 18 May 2025to 29 Jun 2025
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- 1) Participants fully understand the purpose, nature, methods and possible adverse reactions of the trial, voluntarily act as participants, and sign the informed consent form before the start of any study procedures; 2) Healthy male or female participants aged 18 ~ 50 years old (including 18 and 50 years old); 3) Male weight ≥ 50.0 kg, female weight ≥ 45.0 kg, body mass index [BMI = weight (kg)/ height (m)2]: 19.0-26.0 kg/m2, including 19.0 and 26.0 kg/m2; 4) The results of vital signs, physical examination, 12-lead electrocardiogram examination, abdominal B-ultrasound (liver, gallbladder, pancreas, spleen, kidney), chest X-ray and laboratory examination (blood routine, urine routine, blood biochemistry, coagulation function, four items before blood transfusion, fecal occult blood examination) are normal or judged by the investigator to be abnormal of no clinical significance; 5) Participants (including male participants) have no fertility plan and voluntarily take effective contraceptive measures (contraceptive measures other than contraceptive drugs during the trial) within 3 months after signing the informed consent form to dosing, and have no sperm donation and egg donation plans; 6) Able to communicate well with the investigator, and understand and comply with the requirements of the trial.
Who cannot join
- 1) People with allergies: allergies to medicines, food, pollen, etc., or those who have a history of allergy to repaglinide tablets, warfarin sodium tablets, omeprazole enteric-coated capsules, Y-3 for injection or any of components of above investigational products; 2) Those who have diseases or medical history that may affect drug absorption, distribution, metabolism, excretion or interpretation of safety data, or diseases or medical history that can reduce compliance, including but not limited to gastrointestinal, renal, hepatic, pulmonary, neurological, hematological, endocrine, tumor, immunologic, psychiatric or cardiovascular and cerebrovascular diseases (especially liver and kidney insufficiency, diabetes, hypoglycemia, bleeding tendency or cachexia, malignant hypertension, thrombocytopenia); 3) Those who have undergone surgery within 6 months before the first use of the investigational products, or have undergone surgery that will affect the absorption, distribution, metabolism, and excretion of the investigational products, or plan to undergo surgery during the trial; 4) Those who have a history of fainting needle and blood sickness, cannot tolerate venipuncture blood collection, cannot tolerate intravenous administration and/or have difficulty in blood collection; 5) Those who cannot comply with the uniform diet (such as special dietary requirements, intolerance to standard meals, etc.); 6) For patients with creatinine clearance <80 mL/min, creatinine clearance (mL/min) = [(140-age) × body weight (kg)]/[72×Scr(mg/dl)] or creatinine clearance (mL/min) = [(140-age) × body weight(kg)]/[0.818×Scr(μmol/L)], female study participants were × 0.85 according to the calculated results; 7) Those who have participated in or are participating in other clinical trials within 3 months before the first use of the investigational products (drug clinical trial is defined as the use of clinical investigational products), or plan to participate in other clinical trials during the trial period or within 1 month after the end of the trial, or those who do not come to participate in clinical trials in person; 8) Those who have donated blood (including component blood) or had heavy bleeding (greater than 400 ml, except for blood loss during normal menstrual period in women) within 3 months before the first use of the investigational products, or received blood transfusion or used blood products, or plan to donate blood or blood components during the study or within 1 month after the end of the study; 9) Those who have had significant changes in diet or exercise habits within 3 months before the first use of the investigational products; 10) Those who have an average daily smoking volume of more than 5 cigarettes within 3 months before the first use of the investigational products, or cannot stop using any tobacco products (including any smoking cessation products containing nicotine) within 48 hours before the first use of the investigational products and during the trial; 11) Those who have a history of drug abuse or drug use within 6 months before the first use of the investigational products, or who are positive for drug abuse screening (morphine, methamphetamine, ketamine, tetrahydrocannabinolic acid, dimethylenedioxyamphetamine); 12) Those who have consumed more than 14 units of alcohol per week (1 unit of alcohol ≈ 360 mL of beer or 45 mL of spirits with 40% alcohol content or 150 mL of wine) per week within 3 months before the first use of the investigational products, or who cannot abstain from alcohol or stop using any diet containing alcohol within 48 hours before the first use of the investigational products and during the trial, or have a positive alcohol breath test result (greater than 0.0 mg/100 mL); 13) Those who consume excessive amounts of tea, coffee and/or caffeine-rich beverages (more than 8 cups, 1 cup = 250 mL) every day within 3 months before the first use of the investigational products, or cannot stop using caffeine-rich foods or beverages (such as chocolate, coffee, tea, cola, etc.) within 48 hours before the first use of the investigational products and during the trial; 14) Those who have used any drug that can change the activity of liver drug enzymes within 1 month before the first use of the investigational products; 15) Those who have been vaccinated within 1 month before the first use of the investigational products, or plan to receive any vaccine during the trial or within one week after the end of the trial; 16) Those who have used any prescription medicines, over-the-counter medicines, Chinese herbal medicines, health products and functional vitamins within 14 days before the first use of the investigational products; 17) Those who have one or more positive test results for hepatitis B surface antigen, hepatitis C virus antibody, HIV1/2 antigen/antibody and treponema pallidum antibody; 18) Females of childbearing potential who have had unprotected sex within 14 days prior to the first use of investigational products, or females who are pregnant or lactating, or who have a positive pregnancy test result; 19) Those who cannot stop ingesting grapefruit, dragon fruit, mango, lime, star fruit and other fruits or related products that affect metabolic enzymes within 48 hours before the first use of the investigational products and during the test; 20) Other conditions judged by the investigator to be inappropriate for enrollment.
Trial locations and contacts
1 site in 1 country.
China1 site
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui
About this study
Official title: Study of the Pharmacokinetic Effect of Y-3 for Injection on Repaglinide Tablets, Warfarin Sodium Tablets, and Omeprazole Enteric-Coated Capsules in Healthy Participants
The primary goal of this clinical trial is to evaluate the effect of Y-3 for injection on the pharmacokinetic profile of the sensitive finger substrates repaglinide tablets, warfarin sodium tablets, and omeprazole enteric-coated capsules for CYP2C8, CYP2C9, and CYP2C19 in Chinese healthy participants, to evaluate whether Y-3 for injection(40mg) will have clinical drug interactions with repaglinide tablets, warfarin sodium tablets and omeprazole enteric-coated capsules, so as to provide a reference for the drafting of Y-3 drug instructions for injection and a basis for the safe and rational use of the drug after marketing. The secondary goal of this clinical trial is to observe the effect of Y-3 for injection on the safety of repaglinide tablets, warfarin sodium tablets and omeprazole enteric-coated capsules. The main questions it aims to answer are:
What the pharmacokinetic profiles of repaglinide tablets, warfarin sodium tablets, and omeprazole enteric-coated capsules when using Y-3 (40 mg) in healthy participants.
Read more
If Y-3 for injection (40mg) will have clinical drug interactions with repaglinide tablets, warfarin sodium tablets and omeprazole enteric-coated capsules If Y-3 for injection (40mg) is safe in participants who using repaglinide tablets, warfarin sodium tablets, and omeprazole enteric-coated capsules.
Researchers will see what the pharmacokinetic profiles and safety of repaglinide tablets, warfarin sodium tablets, and omeprazole enteric-coated capsules when using Y-3 (40 mg) in healthy participants.
Participants will:
Take repaglinide tablets, warfarin sodium tablets and omeprazole enteric-coated capsules without Y-3.
Take repaglinide tablets, warfarin sodium tablets and omeprazole enteric-coated capsules during the use of Y-3.
Answer questions regarding your medical history. Comply with the study procedures and requests. Complete all tests and collections of PK Sampling. Must not have any special dietary requirements and be able to consume the food (low-fat) provided by Tranquil Clinical Research during your 4-night stay.
Must avoid excessive (> 8 cups per day) caffeine consumption (i.e. coffee or tea) during your time in the study.
Must not consume any food or beverage rich in grapefruit, papaya, or mango during your time in the study.
Must not take any other medications, including traditional Chinese medicines and herbal medicines, during your time in the study.
Must avoid sexual activity or use non-drug contraceptive measures (i.e. condoms) during your time in the study.
Female participants must not become pregnant while in the study. Must not receive any vaccinations during your time in the study. Must not donate blood for purposes outside of study procedures during your time in the study.
Must not drink alcohol during your time in the study. Must not smoke during your time in the study. Inform your Study Doctor if you no longer wish to participate in the study.
- Conditions
- Pharmacokinetic Profiles, Y-3 for Injection, Drug-drug Interaction, Repaglinide Tablets, Warfarin Sodium Tablets, Omeprazole Enteric-coated Capsules
- Being tested
- sequentially single use of repaglinide, warfarin and omeprazole or combined with Y-3
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
sequentially single use of repaglinide, warfarin and omeprazole or combined with Y-3Drug
Take repaglinide tablets, warfarin sodium tablets and omeprazole enteric-coated capsules without Y-3.
Take repaglinide tablets, warfarin sodium tablets and omeprazole enteric-coated capsules sequentially during the use of Y-3.
| Study group | Role | What they receive |
|---|---|---|
| use of repaglinide, warfarin, and omeprazole or combined with Y-3 | Experimental | Not described Receives: Drug: sequentially single use of repaglinide, warfarin and omeprazole or combined with Y-3 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluate the AUC0-t of repaglinide in the healthy participants by venous blood and Phoenix WinNonlin.
Area under the concentration-time curve from time 0 to the time of the last quantifiable concentration.
Calculated according to linearity trapezoidal rule:
AUC (i, i+1) = (Ti+1-Ti) (Ci+Ci+1) /2, and AUC0-t is the sum of all AUC (i, i + 1).
Measured: on Day 1 and Day 16 of observation period
Evaluate the AUC0-t of S-warfarin in the healthy participants by venous blood and Phoenix WinNonlin.
Area under the concentration-time curve from time 0 to the time of the last quantifiable concentration.
Calculated according to linearity trapezoidal rule:
AUC (i, i+1) = (Ti+1-Ti) (Ci+Ci+1) /2, and AUC0-t is the sum of all AUC (i, i + 1).
Measured: On Day 3, Day 4, Day 5, Day 7, Day 9, Day 11, Day 18, Day 19, Day 20, Day 22, Day 24 of observation period.
Evaluate the AUC0-t of omeprazole in the healthy participants by venous blood and Phoenix WinNonlin.
Area under the concentration-time curve from time 0 to the time of the last quantifiable concentration.
Calculated according to linearity trapezoidal rule:
AUC (i, i+1) = (Ti+1-Ti) (Ci+Ci+1) /2, and AUC0-t is the sum of all AUC (i, i + 1).
Measured: On Day 3, Day 4, Day 5, Day 7, Day 9, Day 11, Day 18, Day 19, Day 20, Day 22, Day 24 of observation period.
Evaluate the AUC 0-∞of repaglinide in the healthy participants by venous blood and Phoenix WinNonlin.
Area under the concentration-time curve from time 0 to infinity (extrapolated). AUC 0-∞ =AUC 0-t + Ct/λz (Ct is the last measured plasma concentration).
Measured: On Day 1, Day 16 of observation period.
Evaluate the AUC0-∞ of S-warfarin in the healthy participants by venous blood and Phoenix WinNonlin.
Area under the concentration-time curve from time 0 to infinity (extrapolated). AUC 0-∞ =AUC 0-t + Ct/λz (Ct is the last measured plasma concentration).
Measured: On Day 3, Day 4, Day 5, Day 7, Day 9, Day 11, Day 18, Day 19, Day 20, Day 22, Day 24 of observation period.
Evaluate the AUC0-∞ of omeprazole in the healthy participants by venous blood and Phoenix WinNonlin.
Area under the concentration-time curve from time 0 to infinity (extrapolated). AUC 0-∞ =AUC 0-t + Ct/λz (Ct is the last measured plasma concentration).
Measured: On Day 3, Day 4, Day 5, Day 7, Day 9, Day 11, Day 18, Day 19, Day 20, Day 22, Day 24 of observation period.
Secondary outcomes (39)
Evaluate the Cmax of repaglinide in the healthy participants by venous blood and Phoenix WinNonlin.
Maximum observed plasma concentration. It was obtained directly from the measured plasma concentration-time data.
Measured: On Day 1, Day 16 of observation period.
Evaluate the Cmax of S-warfarin in the healthy participants by venous blood and Phoenix WinNonlin.
Maximum observed plasma concentration. It was obtained directly from the measured plasma concentration-time data.
Measured: On Day 3, Day 4, Day 5, Day 7, Day 9, Day 11, Day 18, Day 19, Day 20, Day 22, Day 24 of observation period.
Evaluate the Cmax of omeprazole in the healthy participants by venous blood and Phoenix WinNonlin.
Maximum observed plasma concentration. It was obtained directly from the measured plasma concentration-time data.
Measured: On Day 3, Day 4, Day 5, Day 7, Day 9, Day 11, Day 18, Day 19, Day 20, Day 22, Day 24 of observation period.
Evaluate the Tmax of repaglinide in the healthy participants by venous blood and Phoenix WinNonlin.
Time to reach maximum observed plasma concentration. It was obtained directly from the measured plasma concentration-time data.
Measured: On Day 1, Day 16 of observation period.
Evaluate the Tmax of S-warfarin in the healthy participants by venous blood and Phoenix WinNonlin.
Time to reach maximum observed plasma concentration. It was obtained directly from the measured plasma concentration-time data.
Measured: On Day 3, Day 4, Day 5, Day 7, Day 9, Day 11, Day 18, Day 19, Day 20, Day 22, Day 24 of observation period.
Evaluate the Tmax of omeprazole in the healthy participants by venous blood and Phoenix WinNonlin.
Time to reach maximum observed plasma concentration. It was obtained directly from the measured plasma concentration-time data.
Measured: On Day 3, Day 4, Day 5, Day 7, Day 9, Day 11, Day 18, Day 19, Day 20, Day 22, Day 24 of observation period.
Evaluate the t1/2z of repaglinide in the healthy participants by venous blood and Phoenix WinNonlin.
Terminal elimination half-life.
Measured: On Day 1, Day 16 of observation period.
Evaluate the t1/2z of S-warfarin in the healthy participants by venous blood and Phoenix WinNonlin.
Terminal elimination half-life.
Measured: On Day 3, Day 4, Day 5, Day 7, Day 9, Day 11, Day 18, Day 19, Day 20, Day 22, Day 24 of observation period.
Evaluate the t1/2z of omeprazole in the healthy participants by venous blood and Phoenix WinNonlin.
Terminal elimination half-life.
Measured: On Day 3, Day 4, Day 5, Day 7, Day 9, Day 11, Day 18, Day 19, Day 20, Day 22, Day 24 of observation period.
Evaluate the λz of repaglinide in the healthy participants by venous blood and Phoenix WinNonlin.
Terminal-phase elimination rate constant, slope of curves terminal segment at semi-log concentration-time curve calculated by linear regression.
Measured: On Day 1, Day 16 of observation period.
Evaluate the λz of S-warfarin in the healthy participants by venous blood and Phoenix WinNonlin.
Terminal-phase elimination rate constant, slope of curves terminal segment at semi-log concentration-time curve calculated by linear regression.
Measured: On Day 3, Day 4, Day 5, Day 7, Day 9, Day 11, Day 18, Day 19, Day 20, Day 22, Day 24 of observation period.
Evaluate the λz of omeprazole in the healthy participants by venous blood and Phoenix WinNonlin.
Terminal-phase elimination rate constant, slope of curves terminal segment at semi-log concentration-time curve calculated by linear regression.
Measured: On Day 3, Day 4, Day 5, Day 7, Day 9, Day 11, Day 18, Day 19, Day 20, Day 22, Day 24 of observation period.
Evaluate the AUC_%Extrap of repaglinide in the healthy participants by venous blood and Phoenix WinNonlin
The percentage of the AUC0-inf that has been extrapolated. AUC_%Extrap = [(AUC0-∞-AUC0-t)/AUC0-∞] × 100%
Measured: On Day 1, Day 16 of observation period.
Evaluate the AUC_%Extrap of S-warfarin in the healthy participants by venous blood and Phoenix WinNonlin
The percentage of the AUC0-inf that has been extrapolated. AUC_%Extrap = [(AUC0-∞-AUC0-t)/AUC0-∞] × 100%
Measured: On Day 3, Day 4, Day 5, Day 7, Day 9, Day 11, Day 18, Day 19, Day 20, Day 22, Day 24 of observation period.
Evaluate the AUC_%Extrap of omeprazole in the healthy participants by venous blood and Phoenix WinNonlin
The percentage of the AUC0-inf that has been extrapolated. AUC_%Extrap = [(AUC0-∞-AUC0-t)/AUC0-∞] × 100%
Measured: On Day 3, Day 4, Day 5, Day 7, Day 9, Day 11, Day 18, Day 19, Day 20, Day 22, Day 24 of observation period.
Evaluate the Vz/F of repaglinide in the healthy participants by venous blood and Phoenix WinNonlin
Volume of distribution. Vz/F= CLz/F/λz
Measured: On Day 1, Day 16 of observation period.
Evaluate the Vz/F of S-warfarin in the healthy participants by venous blood and Phoenix WinNonlin
Volume of distribution. Vz/F= CLz/F/λz
Measured: On Day 3, Day 4, Day 5, Day 7, Day 9, Day 11, Day 18, Day 19, Day 20, Day 22, Day 24 of observation period.
Evaluate the Vz/F of omeprazole in the healthy participants by venous blood and Phoenix WinNonlin
Volume of distribution. Vz/F= CLz/F/λz
Measured: On Day 3, Day 4, Day 5, Day 7, Day 9, Day 11, Day 18, Day 19, Day 20, Day 22, Day 24 of observation period.
Evaluate the CLz/F of repaglinide in the healthy participants by venous blood and Phoenix WinNonlin
Total body clearance. CLz/F=dosage/AUC0-∞
Measured: On Day 1, Day 16 of observation period.
Evaluate the CLz/F of S-warfarin in the healthy participants by venous blood and Phoenix WinNonlin
Total body clearance. CLz/F=dosage/AUC0-∞
Measured: On Day 3, Day 4, Day 5, Day 7, Day 9, Day 11, Day 18, Day 19, Day 20, Day 22, Day 24 of observation period.
Evaluate the CLz/F of omeprazole in the healthy participants by venous blood and Phoenix WinNonlin
Total body clearance. CLz/F=dosage/AUC0-∞
Measured: On Day 3, Day 4, Day 5, Day 7, Day 9, Day 11, Day 18, Day 19, Day 20, Day 22, Day 24 of observation period.
Evaluate the safety of repaglinide in the healthy participants taking Y-3 (40 mg) by the rate of adverse events.
An AE is defined as any untoward medical event that occurs after receiving a drug or treatment or any deterioration of a disease or symptom that existed before receiving the investigational product or treatment (excluding the disease studied in this trial) in a subject or a clinical investigation subject, whether or not considered related to the investigational product or treatment. Therefore, an AE can be a discomfort sign (including an abnormal laboratory finding), symptom, or transient disease beyond any indication, whether or not related to the investigational product or treatment.
The investigator will name each AE reported during the study by MedDRA PT and evaluate their severity using the criteria of "mild", "moderate" and "severe".
The relevance evaluation is divided into 5 grades: 1-certainly related; 2- probably/likely related; 3-possibly related; 4-unlikely related; 5 not related.
Measured: Observation period and follow-up period. Day 1~Day 36.
Evaluate the safety of S-warfarin in the healthy participants taking Y-3 (40 mg) by the rate of adverse events.
An AE is defined as any untoward medical event that occurs after receiving a drug or treatment or any deterioration of a disease or symptom that existed before receiving the investigational product or treatment (excluding the disease studied in this trial) in a subject or a clinical investigation subject, whether or not considered related to the investigational product or treatment. Therefore, an AE can be a discomfort sign (including an abnormal laboratory finding), symptom, or transient disease beyond any indication, whether or not related to the investigational product or treatment.
The investigator will name each AE reported during the study by MedDRA PT and evaluate their severity using the criteria of "mild", "moderate" and "severe".
The relevance evaluation is divided into 5 grades: 1-certainly related; 2- probably/likely related; 3-possibly related; 4-unlikely related; 5 not related.
Measured: Observation period and follow-up period. Day 1~Day 36.
Evaluate the safety of omeprazole in the healthy participants taking Y-3 (40 mg) by the rate of adverse events.
An AE is defined as any untoward medical event that occurs after receiving a drug or treatment or any deterioration of a disease or symptom that existed before receiving the investigational product or treatment (excluding the disease studied in this trial) in a subject or a clinical investigation subject, whether or not considered related to the investigational product or treatment. Therefore, an AE can be a discomfort sign (including an abnormal laboratory finding), symptom, or transient disease beyond any indication, whether or not related to the investigational product or treatment.
The investigator will name each AE reported during the study by MedDRA PT and evaluate their severity using the criteria of "mild", "moderate" and "severe".
The relevance evaluation is divided into 5 grades: 1-certainly related; 2- probably/likely related; 3-possibly related; 4-unlikely related; 5 not related.
Measured: Observation period and follow-up period. Day 1~Day 36.
Evaluate the safety of repaglinide in the healthy participants taking Y-3 (40 mg) by the incidence of subject getting abnormal results of vital signs.
Record changes from baseline to post-treatment, listing deviations from normal ranges post-treatment. Vital signs(blood pressure, respiration, pulse, body temperature） will be assessed by according equipments.(electronic sphygmomanometer，thermometer).
Measured: The whole study period. Day -14 ~ Day 36.
Evaluate the safety of S-warfarin in the healthy participants taking Y-3 (40 mg) by the incidence of subject getting abnormal results of vital signs.
Record changes from baseline to post-treatment, listing deviations from normal ranges post-treatment. Vital signs(blood pressure, respiration, pulse, body temperature） will be assessed by according equipments.(electronic sphygmomanometer，thermometer).
Measured: The whole study period. Day -14 ~ Day 36
Evaluate the safety of omeprazole in the healthy participants taking Y-3 (40 mg) by the incidence of subject getting abnormal results of vital signs.
Record changes from baseline to post-treatment, listing deviations from normal ranges post-treatment. Vital signs(blood pressure, respiration, pulse, body temperature） will be assessed by according equipments.(electronic sphygmomanometer，thermometer).
Measured: The whole study period. Day -14~Day 36.
Evaluate the safety of repaglinide in the healthy participants taking Y-3 (40 mg) by the incidence of subject getting abnormal results of physical examinations
Record changes from baseline to post-treatment, listing deviations from normal ranges post-treatment. Physical examinations will be conduct by the investigator through observation.
Measured: The whole study period. Day -14 ~ Day 36.
Evaluate the safety of S-warfarin in the healthy participants taking Y-3 (40 mg) by the incidence of subject getting abnormal results of physical examinations
Record changes from baseline to post-treatment, listing deviations from normal ranges post-treatment. Physical examinations will be conduct by the investigator through observation.
Measured: The whole study period. Day -14 ~ Day 36.
Evaluate the safety of omeprazole in the healthy participants taking Y-3 (40 mg) by the incidence of subject getting abnormal results of physical examinations
Record changes from baseline to post-treatment, listing deviations from normal ranges post-treatment. Physical examinations will be conduct by the investigator through observation.
Measured: The whole study period. Day -14 ~ Day 36.
Evaluate the safety of repaglinide in the healthy participants taking Y-3 (40 mg) by the incidence of subject have infusion-related reactions
infusion-related reactions is a general term for the adverse reactions related to infusion caused by the clinical use of intravenous preparations, including febrile reactions, circulatory overload reactions, phlebitis, air embolism, etc.
Measured: Observation period. Day 12~Day 25.
Evaluate the safety of S-warfarin in the healthy participants taking Y-3 (40 mg) by the incidence of subject have infusion-related reactions
infusion-related reactions is a general term for the adverse reactions related to infusion caused by the clinical use of intravenous preparations, including febrile reactions, circulatory overload reactions, phlebitis, air embolism, etc.
Measured: Observation period. Day 12~Day 25.
Evaluate the safety of omeprazole in the healthy participants taking Y-3 (40 mg) by the incidence of subject have infusion-related reactions
infusion-related reactions is a general term for the adverse reactions related to infusion caused by the clinical use of intravenous preparations, including febrile reactions, circulatory overload reactions, phlebitis, air embolism, etc.
Measured: Observation period. Day 12~Day 25.
Evaluate the safety of repaglinide in the healthy participants taking Y-3 (40 mg) by the incidence of subject getting abnormal results of laboratory tests
Record changes from baseline to post-treatment, listing deviations from normal ranges post-treatment. Laboratory tests are composed of hematology, urinalysis, serum chemistry, coagulation test. Normal range is provided by the site.
Measured: The whole study period. Day -14 ~ Day 36.
Evaluate the safety of S-warfarin in the healthy participants taking Y-3 (40 mg) by the incidence of subject getting abnormal results of laboratory tests
Record changes from baseline to post-treatment, listing deviations from normal ranges post-treatment. Laboratory tests are composed of hematology, urinalysis, serum chemistry, coagulation test. Normal range is provided by the site.
Measured: The whole study period. Day -14 ~ Day 36.
Evaluate the safety of omeprazole in the healthy participants taking Y-3 (40 mg) by the incidence of subject getting abnormal results of laboratory tests
Record changes from baseline to post-treatment, listing deviations from normal ranges post-treatment. Laboratory tests are composed of hematology, urinalysis, serum chemistry, coagulation test. Normal range is provided by the site.
Measured: The whole study period. Day -14 ~ Day 36.
Evaluate the safety of repaglinide in the healthy participants taking Y-3 (40 mg) by the incidence of subject getting abnormal results of 12-lead ECG
Record changes from baseline to post-treatment, listing deviations from normal ranges post-treatment. 12-lead ECG will be analyzed by single RR Heart Rate, aggregate PR Interval, aggregate QRS Duration, aggregate RR Interval, aggregate QT Interval, aggregate QTC Interval. Normal range is provided by the site.
Measured: The whole study period. Day -14 ~ Day 36.
Evaluate the safety of S-warfarin in the healthy participants taking Y-3 (40 mg) by the incidence of subject getting abnormal results of 12-lead ECG
Record changes from baseline to post-treatment, listing deviations from normal ranges post-treatment. 12-lead ECG will be analyzed by single RR Heart Rate, aggregate PR Interval, aggregate QRS Duration, aggregate RR Interval, aggregate QT Interval, aggregate QTC Interval. Normal range is provided by the site.
Measured: The whole study period. Day -14~Day 36.
Evaluate the safety of omeprazole in the healthy participants taking Y-3 (40 mg) by the incidence of subject getting abnormal results of 12-lead ECG
Record changes from baseline to post-treatment, listing deviations from normal ranges post-treatment. 12-lead ECG will be analyzed by single RR Heart Rate, aggregate PR Interval, aggregate QRS Duration, aggregate RR Interval, aggregate QT Interval, aggregate QTC Interval. Normal range is provided by the site.
Measured: The whole study period. Day -14 ~ Day 36.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jul 2025
- Study start18 May 2025
- Primary completion29 Jun 2025
- Study completion29 Jun 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pharmacokinetic ProfilesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 24 participants (actual)
Sponsor and investigators
- Lead sponsor
- Neurodawn Pharmaceutical Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07068841
- Sponsor's protocol ID
- Y-3-LC-08
- Status last verified
- Dec 2025
- First submitted
- 27 Jun 2025
- Last updated
- 22 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of the Pharmacokinetic Effect of Y-3 for Injection on Repaglinide Tablets, Warfarin Sodium Tablets, and Omeprazole Enteric-Coated Capsules in Healthy Participants
- ClinicalTrials.gov ID
- NCT07068841
- Acronym / sponsor ID
- Y-3-LC-08
- Conditions
- Pharmacokinetic Profiles, Y-3 for Injection, Drug-drug Interaction, Repaglinide Tablets, Warfarin Sodium Tablets, Omeprazole Enteric-coated Capsules
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 24 participants (actual)
- Lead sponsor
- Neurodawn Pharmaceutical Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- 18 May 2025 (actual)
- Primary completion
- 29 Jun 2025 (actual)
- Study completion
- 29 Jun 2025 (actual)
- First posted
- 16 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary goal of this clinical trial is to evaluate the effect of Y-3 for injection on the pharmacokinetic profile of the sensitive finger substrates repaglinide tablets, warfarin sodium tablets, and omeprazole enteric-coated capsules for CYP2C8, CYP2C9, and CYP2C19 in Chinese healthy participants, to evaluate whether Y-3 for injection(40mg) will have clinical drug interactions with repaglinide tablets, warfarin sodium tablets and omeprazole enteric-coated capsules, so as to provide a reference for the drafting of Y-3 drug instructions for injection and a basis for the safe and rational use of the drug after marketing. The secondary goal of this clinical trial is to observe the effect of Y-3 for injection on the safety of repaglinide tablets, warfarin sodium tablets and omeprazole enteric-coated capsules. The main questions it aims to answer are:
What the pharmacokinetic profiles of repaglinide tablets, warfarin sodium tablets, and omeprazole enteric-coated capsules when using Y-3 (40 mg) in healthy participants.
If Y-3 for injection (40mg) will have clinical drug interactions with repaglinide tablets, warfarin sodium tablets and omeprazole enteric-coated capsules If Y-3 for injection (40mg) is safe in participants who using repaglinide tablets, warfarin sodium tablets, and omeprazole enteric-coated capsules.
Researchers will see what the pharmacokinetic profiles and safety of repaglinide tablets, warfarin sodium tablets, and omeprazole enteric-coated capsules when using Y-3 (40 mg) in healthy participants.
Participants will:
Take repaglinide tablets, warfarin sodium tablets and omeprazole enteric-coated capsules without Y-3.
Take repaglinide tablets, warfarin sodium tablets and omeprazole enteric-coated capsules during the use of Y-3.
Answer questions regarding your medical history. Comply with the study procedures and requests. Complete all tests and collections of PK Sampling. Must not have any special dietary requirements and be able to consume the food (low-fat) provided by Tranquil Clinical Research during your 4-night stay.
Must avoid excessive (> 8 cups per day) caffeine consumption (i.e. coffee or tea) during your time in the study.
Must not consume any food or beverage rich in grapefruit, papaya, or mango during your time in the study.
Must not take any other medications, including traditional Chinese medicines and herbal medicines, during your time in the study.
Must avoid sexual activity or use non-drug contraceptive measures (i.e. condoms) during your time in the study.
Female participants must not become pregnant while in the study. Must not receive any vaccinations during your time in the study. Must not donate blood for purposes outside of study procedures during your time in the study.
Must not drink alcohol during your time in the study. Must not smoke during your time in the study. Inform your Study Doctor if you no longer wish to participate in the study.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| use of repaglinide, warfarin, and omeprazole or combined with Y-3 | Experimental | Drug: sequentially single use of repaglinide, warfarin and omeprazole or combined with Y-3 |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- 1) Participants fully understand the purpose, nature, methods and possible adverse reactions of the trial, voluntarily act as participants, and sign the informed consent form before the start of any study procedures; 2) Healthy male or female participants aged 18 ~ 50 years old (including 18 and 50 years old); 3) Male weight ≥ 50.0 kg, female weight ≥ 45.0 kg, body mass index [BMI = weight (kg)/ height (m)2]: 19.0-26.0 kg/m2, including 19.0 and 26.0 kg/m2; 4) The results of vital signs, physical examination, 12-lead electrocardiogram examination, abdominal B-ultrasound (liver, gallbladder, pancreas, spleen, kidney), chest X-ray and laboratory examination (blood routine, urine routine, blood biochemistry, coagulation function, four items before blood transfusion, fecal occult blood examination) are normal or judged by the investigator to be abnormal of no clinical significance; 5) Participants (including male participants) have no fertility plan and voluntarily take effective contraceptive measures (contraceptive measures other than contraceptive drugs during the trial) within 3 months after signing the informed consent form to dosing, and have no sperm donation and egg donation plans; 6) Able to communicate well with the investigator, and understand and comply with the requirements of the trial.
Key exclusion criteria (1 listed)
- 1) People with allergies: allergies to medicines, food, pollen, etc., or those who have a history of allergy to repaglinide tablets, warfarin sodium tablets, omeprazole enteric-coated capsules, Y-3 for injection or any of components of above investigational products; 2) Those who have diseases or medical history that may affect drug absorption, distribution, metabolism, excretion or interpretation of safety data, or diseases or medical history that can reduce compliance, including but not limited to gastrointestinal, renal, hepatic, pulmonary, neurological, hematological, endocrine, tumor, immunologic, psychiatric or cardiovascular and cerebrovascular diseases (especially liver and kidney insufficiency, diabetes, hypoglycemia, bleeding tendency or cachexia, malignant hypertension, thrombocytopenia); 3) Those who have undergone surgery within 6 months before the first use of the investigational products, or have undergone surgery that will affect the absorption, distribution, metabolism, and excretion of the investigational products, or plan to undergo surgery during the trial; 4) Those who have a history of fainting needle and blood sickness, cannot tolerate venipuncture blood collection, cannot tolerate intravenous administration and/or have difficulty in blood collection; 5) Those who cannot comply with the uniform diet (such as special dietary requirements, intolerance to standard meals, etc.); 6) For patients with creatinine clearance <80 mL/min, creatinine clearance (mL/min) = [(140-age) × body weight (kg)]/[72×Scr(mg/dl)] or creatinine clearance (mL/min) = [(140-age) × body weight(kg)]/[0.818×Scr(μmol/L)], female study participants were × 0.85 according to the calculated results; 7) Those who have participated in or are participating in other clinical trials within 3 months before the first use of the investigational products (drug clinical trial is defined as the use of clinical investigational products), or plan to participate in other clinical trials during the trial period or within 1 month after the end of the trial, or those who do not come to participate in clinical trials in person; 8) Those who have donated blood (including component blood) or had heavy bleeding (greater than 400 ml, except for blood loss during normal menstrual period in women) within 3 months before the first use of the investigational products, or received blood transfusion or used blood products, or plan to donate blood or blood components during the study or within 1 month after the end of the study; 9) Those who have had significant changes in diet or exercise habits within 3 months before the first use of the investigational products; 10) Those who have an average daily smoking volume of more than 5 cigarettes within 3 months before the first use of the investigational products, or cannot stop using any tobacco products (including any smoking cessation products containing nicotine) within 48 hours before the first use of the investigational products and during the trial; 11) Those who have a history of drug abuse or drug use within 6 months before the first use of the investigational products, or who are positive for drug abuse screening (morphine, methamphetamine, ketamine, tetrahydrocannabinolic acid, dimethylenedioxyamphetamine); 12) Those who have consumed more than 14 units of alcohol per week (1 unit of alcohol ≈ 360 mL of beer or 45 mL of spirits with 40% alcohol content or 150 mL of wine) per week within 3 months before the first use of the investigational products, or who cannot abstain from alcohol or stop using any diet containing alcohol within 48 hours before the first use of the investigational products and during the trial, or have a positive alcohol breath test result (greater than 0.0 mg/100 mL); 13) Those who consume excessive amounts of tea, coffee and/or caffeine-rich beverages (more than 8 cups, 1 cup = 250 mL) every day within 3 months before the first use of the investigational products, or cannot stop using caffeine-rich foods or beverages (such as chocolate, coffee, tea, cola, etc.) within 48 hours before the first use of the investigational products and during the trial; 14) Those who have used any drug that can change the activity of liver drug enzymes within 1 month before the first use of the investigational products; 15) Those who have been vaccinated within 1 month before the first use of the investigational products, or plan to receive any vaccine during the trial or within one week after the end of the trial; 16) Those who have used any prescription medicines, over-the-counter medicines, Chinese herbal medicines, health products and functional vitamins within 14 days before the first use of the investigational products; 17) Those who have one or more positive test results for hepatitis B surface antigen, hepatitis C virus antibody, HIV1/2 antigen/antibody and treponema pallidum antibody; 18) Females of childbearing potential who have had unprotected sex within 14 days prior to the first use of investigational products, or females who are pregnant or lactating, or who have a positive pregnancy test result; 19) Those who cannot stop ingesting grapefruit, dragon fruit, mango, lime, star fruit and other fruits or related products that affect metabolic enzymes within 48 hours before the first use of the investigational products and during the test; 20) Other conditions judged by the investigator to be inappropriate for enrollment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| sequentially single use of repaglinide, warfarin and omeprazole or combined with Y-3Take repaglinide tablets, warfarin sodium tablets and omeprazole enteric-coated capsules without Y-3. Take repaglinide tablets, warfarin sodium tablets and omeprazole enteric-coated capsules sequentially during the use of Y-3. | Drug | use of repaglinide, warfarin, and omeprazole or combined with Y-3 |
Primary outcome
Evaluate the AUC0-t of repaglinide in the healthy participants by venous blood and Phoenix WinNonlin.
Time frame: on Day 1 and Day 16 of observation period
Area under the concentration-time curve from time 0 to the time of the last quantifiable concentration. Calculated according to linearity trapezoidal rule: AUC (i, i+1) = (Ti+1-Ti) (Ci+Ci+1) /2, and AUC0-t is the sum of all AUC (i, i + 1).
Evaluate the AUC0-t of S-warfarin in the healthy participants by venous blood and Phoenix WinNonlin.
Time frame: On Day 3, Day 4, Day 5, Day 7, Day 9, Day 11, Day 18, Day 19, Day 20, Day 22, Day 24 of observation period.
Area under the concentration-time curve from time 0 to the time of the last quantifiable concentration. Calculated according to linearity trapezoidal rule: AUC (i, i+1) = (Ti+1-Ti) (Ci+Ci+1) /2, and AUC0-t is the sum of all AUC (i, i + 1).
Evaluate the AUC0-t of omeprazole in the healthy participants by venous blood and Phoenix WinNonlin.
Time frame: On Day 3, Day 4, Day 5, Day 7, Day 9, Day 11, Day 18, Day 19, Day 20, Day 22, Day 24 of observation period.
Area under the concentration-time curve from time 0 to the time of the last quantifiable concentration. Calculated according to linearity trapezoidal rule: AUC (i, i+1) = (Ti+1-Ti) (Ci+Ci+1) /2, and AUC0-t is the sum of all AUC (i, i + 1).
Evaluate the AUC 0-∞of repaglinide in the healthy participants by venous blood and Phoenix WinNonlin.
Time frame: On Day 1, Day 16 of observation period.
Area under the concentration-time curve from time 0 to infinity (extrapolated). AUC 0-∞ =AUC 0-t + Ct/λz (Ct is the last measured plasma concentration).
Evaluate the AUC0-∞ of S-warfarin in the healthy participants by venous blood and Phoenix WinNonlin.
Time frame: On Day 3, Day 4, Day 5, Day 7, Day 9, Day 11, Day 18, Day 19, Day 20, Day 22, Day 24 of observation period.
Area under the concentration-time curve from time 0 to infinity (extrapolated). AUC 0-∞ =AUC 0-t + Ct/λz (Ct is the last measured plasma concentration).
Evaluate the AUC0-∞ of omeprazole in the healthy participants by venous blood and Phoenix WinNonlin.
Time frame: On Day 3, Day 4, Day 5, Day 7, Day 9, Day 11, Day 18, Day 19, Day 20, Day 22, Day 24 of observation period.
Area under the concentration-time curve from time 0 to infinity (extrapolated). AUC 0-∞ =AUC 0-t + Ct/λz (Ct is the last measured plasma concentration).
39 secondary outcomes
Evaluate the Cmax of repaglinide in the healthy participants by venous blood and Phoenix WinNonlin.
Time frame: On Day 1, Day 16 of observation period.
Evaluate the Cmax of S-warfarin in the healthy participants by venous blood and Phoenix WinNonlin.
Time frame: On Day 3, Day 4, Day 5, Day 7, Day 9, Day 11, Day 18, Day 19, Day 20, Day 22, Day 24 of observation period.
Evaluate the Cmax of omeprazole in the healthy participants by venous blood and Phoenix WinNonlin.
Time frame: On Day 3, Day 4, Day 5, Day 7, Day 9, Day 11, Day 18, Day 19, Day 20, Day 22, Day 24 of observation period.
Evaluate the Tmax of repaglinide in the healthy participants by venous blood and Phoenix WinNonlin.
Time frame: On Day 1, Day 16 of observation period.
Evaluate the Tmax of S-warfarin in the healthy participants by venous blood and Phoenix WinNonlin.
Time frame: On Day 3, Day 4, Day 5, Day 7, Day 9, Day 11, Day 18, Day 19, Day 20, Day 22, Day 24 of observation period.
Evaluate the Tmax of omeprazole in the healthy participants by venous blood and Phoenix WinNonlin.
Time frame: On Day 3, Day 4, Day 5, Day 7, Day 9, Day 11, Day 18, Day 19, Day 20, Day 22, Day 24 of observation period.
Evaluate the t1/2z of repaglinide in the healthy participants by venous blood and Phoenix WinNonlin.
Time frame: On Day 1, Day 16 of observation period.
Evaluate the t1/2z of S-warfarin in the healthy participants by venous blood and Phoenix WinNonlin.
Time frame: On Day 3, Day 4, Day 5, Day 7, Day 9, Day 11, Day 18, Day 19, Day 20, Day 22, Day 24 of observation period.
Evaluate the t1/2z of omeprazole in the healthy participants by venous blood and Phoenix WinNonlin.
Time frame: On Day 3, Day 4, Day 5, Day 7, Day 9, Day 11, Day 18, Day 19, Day 20, Day 22, Day 24 of observation period.
Evaluate the λz of repaglinide in the healthy participants by venous blood and Phoenix WinNonlin.
Time frame: On Day 1, Day 16 of observation period.
Evaluate the λz of S-warfarin in the healthy participants by venous blood and Phoenix WinNonlin.
Time frame: On Day 3, Day 4, Day 5, Day 7, Day 9, Day 11, Day 18, Day 19, Day 20, Day 22, Day 24 of observation period.
Evaluate the λz of omeprazole in the healthy participants by venous blood and Phoenix WinNonlin.
Time frame: On Day 3, Day 4, Day 5, Day 7, Day 9, Day 11, Day 18, Day 19, Day 20, Day 22, Day 24 of observation period.
Evaluate the AUC_%Extrap of repaglinide in the healthy participants by venous blood and Phoenix WinNonlin
Time frame: On Day 1, Day 16 of observation period.
Evaluate the AUC_%Extrap of S-warfarin in the healthy participants by venous blood and Phoenix WinNonlin
Time frame: On Day 3, Day 4, Day 5, Day 7, Day 9, Day 11, Day 18, Day 19, Day 20, Day 22, Day 24 of observation period.
Evaluate the AUC_%Extrap of omeprazole in the healthy participants by venous blood and Phoenix WinNonlin
Time frame: On Day 3, Day 4, Day 5, Day 7, Day 9, Day 11, Day 18, Day 19, Day 20, Day 22, Day 24 of observation period.
Evaluate the Vz/F of repaglinide in the healthy participants by venous blood and Phoenix WinNonlin
Time frame: On Day 1, Day 16 of observation period.
Evaluate the Vz/F of S-warfarin in the healthy participants by venous blood and Phoenix WinNonlin
Time frame: On Day 3, Day 4, Day 5, Day 7, Day 9, Day 11, Day 18, Day 19, Day 20, Day 22, Day 24 of observation period.
Evaluate the Vz/F of omeprazole in the healthy participants by venous blood and Phoenix WinNonlin
Time frame: On Day 3, Day 4, Day 5, Day 7, Day 9, Day 11, Day 18, Day 19, Day 20, Day 22, Day 24 of observation period.
Evaluate the CLz/F of repaglinide in the healthy participants by venous blood and Phoenix WinNonlin
Time frame: On Day 1, Day 16 of observation period.
Evaluate the CLz/F of S-warfarin in the healthy participants by venous blood and Phoenix WinNonlin
Time frame: On Day 3, Day 4, Day 5, Day 7, Day 9, Day 11, Day 18, Day 19, Day 20, Day 22, Day 24 of observation period.
Evaluate the CLz/F of omeprazole in the healthy participants by venous blood and Phoenix WinNonlin
Time frame: On Day 3, Day 4, Day 5, Day 7, Day 9, Day 11, Day 18, Day 19, Day 20, Day 22, Day 24 of observation period.
Evaluate the safety of repaglinide in the healthy participants taking Y-3 (40 mg) by the rate of adverse events.
Time frame: Observation period and follow-up period. Day 1~Day 36.
Evaluate the safety of S-warfarin in the healthy participants taking Y-3 (40 mg) by the rate of adverse events.
Time frame: Observation period and follow-up period. Day 1~Day 36.
Evaluate the safety of omeprazole in the healthy participants taking Y-3 (40 mg) by the rate of adverse events.
Time frame: Observation period and follow-up period. Day 1~Day 36.
Evaluate the safety of repaglinide in the healthy participants taking Y-3 (40 mg) by the incidence of subject getting abnormal results of vital signs.
Time frame: The whole study period. Day -14 ~ Day 36.
Evaluate the safety of S-warfarin in the healthy participants taking Y-3 (40 mg) by the incidence of subject getting abnormal results of vital signs.
Time frame: The whole study period. Day -14 ~ Day 36
Evaluate the safety of omeprazole in the healthy participants taking Y-3 (40 mg) by the incidence of subject getting abnormal results of vital signs.
Time frame: The whole study period. Day -14~Day 36.
Evaluate the safety of repaglinide in the healthy participants taking Y-3 (40 mg) by the incidence of subject getting abnormal results of physical examinations
Time frame: The whole study period. Day -14 ~ Day 36.
Evaluate the safety of S-warfarin in the healthy participants taking Y-3 (40 mg) by the incidence of subject getting abnormal results of physical examinations
Time frame: The whole study period. Day -14 ~ Day 36.
Evaluate the safety of omeprazole in the healthy participants taking Y-3 (40 mg) by the incidence of subject getting abnormal results of physical examinations
Time frame: The whole study period. Day -14 ~ Day 36.
Evaluate the safety of repaglinide in the healthy participants taking Y-3 (40 mg) by the incidence of subject have infusion-related reactions
Time frame: Observation period. Day 12~Day 25.
Evaluate the safety of S-warfarin in the healthy participants taking Y-3 (40 mg) by the incidence of subject have infusion-related reactions
Time frame: Observation period. Day 12~Day 25.
Evaluate the safety of omeprazole in the healthy participants taking Y-3 (40 mg) by the incidence of subject have infusion-related reactions
Time frame: Observation period. Day 12~Day 25.
Evaluate the safety of repaglinide in the healthy participants taking Y-3 (40 mg) by the incidence of subject getting abnormal results of laboratory tests
Time frame: The whole study period. Day -14 ~ Day 36.
Evaluate the safety of S-warfarin in the healthy participants taking Y-3 (40 mg) by the incidence of subject getting abnormal results of laboratory tests
Time frame: The whole study period. Day -14 ~ Day 36.
Evaluate the safety of omeprazole in the healthy participants taking Y-3 (40 mg) by the incidence of subject getting abnormal results of laboratory tests
Time frame: The whole study period. Day -14 ~ Day 36.
Evaluate the safety of repaglinide in the healthy participants taking Y-3 (40 mg) by the incidence of subject getting abnormal results of 12-lead ECG
Time frame: The whole study period. Day -14 ~ Day 36.
Evaluate the safety of S-warfarin in the healthy participants taking Y-3 (40 mg) by the incidence of subject getting abnormal results of 12-lead ECG
Time frame: The whole study period. Day -14~Day 36.
Evaluate the safety of omeprazole in the healthy participants taking Y-3 (40 mg) by the incidence of subject getting abnormal results of 12-lead ECG
Time frame: The whole study period. Day -14 ~ Day 36.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 May 2026.
- Individual participant dataSharing planned: No
Related trials for Pharmacokinetic Profiles
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
RecruitingPhase 1
Investigation of Pharmacokinetics, Safety of HSK31858 in Subjects With Renal Impairment
Non-cystic Fibrosis Bronchiectasis (NCFBE)
Active, not recruitingPhase 1
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AK0406 Injection in Healthy Adult Participants
Healthy Participants
RecruitingPhase 1
HP007 Monotherapy for Relapsed or Refractory Advanced Solid Tumors
Solid Tumors
RecruitingPhase 1
A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
Prostate Cancer, Other Solid Tumors
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing sequentially single use of repaglinide, warfarin and omeprazole or combined with Y-3 in people with Pharmacokinetic Profiles and Y-3 for Injection, run by Neurodawn Pharmaceutical Co., Ltd. at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evaluate the AUC0-t of repaglinide in the healthy participants by venous blood and Phoenix WinNonlin. (time frame: on Day 1 and Day 16 of observation period). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 May 2026.